Fulgent Genetics Shares Plunge on Wider 4Q Loss, FY Outlook Miss

Dow Jones02-27

By Amira McKee

Shares of Fulgent Genetics tumbled after the company recorded a wider net loss in the fourth quarter and guided for lower-than-expected results in 2026.

The stock plunged 32% to $16.84 in Friday morning trading. The shares have gained 7.9% in the past year.

The medical services company recorded a fourth-quarter net loss of $23.4 million, or 76 cents a share, compared with a loss of $5.9 million, or 19 cents a share, a year earlier.

Adjusted earnings came in at 16 cents a share, beating the 3 cents that Wall Street was expecting, according to FactSet.

Revenue grew 9% to $83.3 million, missing the $85.4 million that analysts polled by FactSet were looking for.

For 2026, Fulgent expects to log a full-year adjusted loss per share of around $1.45 on revenue of around $350.0 million. Wall Street is forecasting an adjusted loss of 32 cents a share on revenue of $356.3 million for the full year.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

February 27, 2026 10:17 ET (15:17 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614223857?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 23:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614223857","market":"us","top_or_hot":-1,"title":"Fulgent Genetics Shares Plunge on Wider 4Q Loss, FY Outlook Miss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics</a> tumbled after the company recorded a wider net loss in the fourth quarter and guided for lower-than-expected results in 2026. \n</p>\n<p>\n  The stock plunged 32% to $16.84 in Friday morning trading. The shares have gained 7.9% in the past year. \n</p>\n<p>\n  The medical services company recorded a fourth-quarter net loss of $23.4 million, or 76 cents a share, compared with a loss of $5.9 million, or 19 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings came in at 16 cents a share, beating the 3 cents that Wall Street was expecting, according to FactSet. \n</p>\n<p>\n  Revenue grew 9% to $83.3 million, missing the $85.4 million that analysts polled by FactSet were looking for. \n</p>\n<p>\n  For 2026, Fulgent expects to log a full-year adjusted loss per share of around $1.45 on revenue of around $350.0 million. Wall Street is forecasting an adjusted loss of 32 cents a share on revenue of $356.3 million for the full year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 27, 2026 10:17 ET (15:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fulgent Genetics Shares Plunge on Wider 4Q Loss, FY Outlook Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFulgent Genetics Shares Plunge on Wider 4Q Loss, FY Outlook Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-27 23:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/FLGT\">Fulgent Genetics</a> tumbled after the company recorded a wider net loss in the fourth quarter and guided for lower-than-expected results in 2026. \n</p>\n<p>\n  The stock plunged 32% to $16.84 in Friday morning trading. The shares have gained 7.9% in the past year. \n</p>\n<p>\n  The medical services company recorded a fourth-quarter net loss of $23.4 million, or 76 cents a share, compared with a loss of $5.9 million, or 19 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings came in at 16 cents a share, beating the 3 cents that Wall Street was expecting, according to FactSet. \n</p>\n<p>\n  Revenue grew 9% to $83.3 million, missing the $85.4 million that analysts polled by FactSet were looking for. \n</p>\n<p>\n  For 2026, Fulgent expects to log a full-year adjusted loss per share of around $1.45 on revenue of around $350.0 million. Wall Street is forecasting an adjusted loss of 32 cents a share on revenue of $356.3 million for the full year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 27, 2026 10:17 ET (15:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FLGT","symbol_name":"Fulgent Genetics Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2614223857","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614223857","pubTimestamp":1772205420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Fulgent Genetics tumbled after the company recorded a wider net loss in the fourth quarter and guided for lower-than-expected results in 2026.The stock plunged 32% to $16.84 in Friday morning trading. The shares have gained 7.9% in the past year.The medical services company recorded a fourth-quarter net loss of $23.4 million, or 76 cents a share, compared with a loss of $5.9 million, or 19 cents a share, a year earlier.Adjusted earnings came in at 16 cents a share, beating the 3 cents that Wall Street was expecting, according to FactSet.Revenue grew 9% to $83.3 million, missing the $85.4 million that analysts polled by FactSet were looking for.For 2026, Fulgent expects to log a full-year adjusted loss per share of around $1.45 on revenue of around $350.0 million. Wall Street is forecasting an adjusted loss of 32 cents a share on revenue of $356.3 million for the full year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FLGT":"Fulgent Genetics Inc.","BK4196":"保健护理服务"},"translate_title":"Fulgent Genetics股价因第四季度亏损扩大而暴跌，财年前景未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FLGT":0.9},"content_text":"By Amira McKee \n\n\n \n\n\n  Shares of Fulgent Genetics tumbled after the company recorded a wider net loss in the fourth quarter and guided for lower-than-expected results in 2026. \n\n\n  The stock plunged 32% to $16.84 in Friday morning trading. The shares have gained 7.9% in the past year. \n\n\n  The medical services company recorded a fourth-quarter net loss of $23.4 million, or 76 cents a share, compared with a loss of $5.9 million, or 19 cents a share, a year earlier. \n\n\n  Adjusted earnings came in at 16 cents a share, beating the 3 cents that Wall Street was expecting, according to FactSet. \n\n\n  Revenue grew 9% to $83.3 million, missing the $85.4 million that analysts polled by FactSet were looking for. \n\n\n  For 2026, Fulgent expects to log a full-year adjusted loss per share of around $1.45 on revenue of around $350.0 million. Wall Street is forecasting an adjusted loss of 32 cents a share on revenue of $356.3 million for the full year. \n\n\n \n\n\n  Write to Amira McKee at amira.mckee@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2026 10:17 ET (15:17 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614223857","isCrawlerRequest":true}